Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβ1
journal contributionposted on 2021-08-06, 00:36 authored by Laura J Vella, Andreas BehrenAndreas Behren, Bradley Coleman, David GreeningDavid Greening, Andrew HillAndrew Hill, Jonathan CebonJonathan Cebon
Treatment of BRAF mutant melanoma with kinase inhibitors has been associated with rapid tumor regression; however, this clinical benefit is short-lived, and most patients relapse. A number of studies suggest that the extracellular environment promotes BRAF inhibitor resistance and tumor progression. Extracellular vesicles, such as exosomes, are functional mediators in the extracellular environment. They are small vesicles known to carry a concentrated group of functional cargo and serve as intercellular communicators not only locally but also systemically. Increasingly, it is reported that extracellular vesicles facilitate the development of drug resistance in cancer; however, their role in BRAF inhibitor resistance in melanoma is unclear. Here we investigated if extracellular vesicles from BRAF inhibitor–resistant melanoma could influence drug sensitivity in recipient melanoma cells. We demonstrate that the resistance driver, PDGFRβ can be transferred to recipient melanoma cells via extracellular vesicles, resulting in a dose-dependent activation of PI3K/AKT signaling and escape from MAPK pathway BRAF inhibition. These data suggest that the BRAF inhibitor–sensitive phenotype of metastatic melanoma can be altered by delivery of PDGFRβ by extracellular vesicles derived from neighboring drug-resistant melanoma cells.
This work was funded in part by Ludwig Cancer Research and by Operational Infrastructure Support Program funding of the Victorian State Government.
Pagination9p. (p. 932-940)
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.
EXOSOMESCANCERTumor Cells, CulturedExtracellular FluidMelanomaProto-Oncogene Proteins B-rafReceptor, Platelet-Derived Growth Factor betaDose-Response Relationship, DrugDrug Resistance, NeoplasmExosomesExtracellular VesiclesOncology & CarcinogenesisBRAF mutant melanomaBRAF inhibitor-resistant melanomaPDGFRβ